Skip to main content
SpringerLink
Log in

Atazanavir

A Review of its Use in the Management of HIV Infection

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Atazanavir (Reyataz®) is a novel protease inhibitor (PI) approved for use in combination with other antiretroviral drugs for the treatment of HIV infection. In antiretroviral therapy (ART)-experienced patients the drug is administered with low-dose ritonavir (i.e. boosted). In the US, unboosted atazanavir is also approved for use in ART-naive patients.

In adult patients with HIV infection, atazanavir-containing highly active antiretroviral therapy (HAART) regimens provided marked improvements in virological and immunological markers and was generally well tolerated. Furthermore, recommended atazanavir regimens were no less effective than, and generally as well tolerated as, other HAART regimens in these patients, including regimens containing co-formulated lopinavir/ritonavir. Atazanavir may have an advantage over other PIs because of its favourable effect on lipid profiles, once-daily dosing, low capsule burden and, in patients with low prior PI exposure, a favourable resistance profile. Given these advantages and taking into consideration between-country differences in the approved indications, atazanavir is a valuable option as the PI component of HAART for the management of HIV infection in adult ART-naive patients, particularly where metabolic complications are a concern, and as a first-or second-line PI in combination with low-dose ritonavir in adult ART-experienced patients.

Pharmacological Properties

Atazanavir prevents the formation of mature virions by inhibiting the processing of viral gag and gag-pol polyproteins in HIV-infected cells. The unique, signature mutation for atazanavir resistance in isolates from ART-naive patients was an isoleucine to leucine substitution at amino acid residue 50 of the HIV-1 protease gene. This mutation was atazanavir-specific and conferred increased susceptibility to other PIs. However, in ART-experienced patients who had never previously received atazanavir, atazanavir susceptibility was reduced in the presence of multiple mutations associated with resistance to other PIs. There was high cross-resistance to atazanavir in patients with prior exposure to at least three other PIs.

Limited data suggest that atazanavir-containing regimens were not associated with insulin resistance, and evidence from clinical trials showed that atazanavir had a lower propensity to cause dyslipidaemia than nelfinavir or efavirenz in ART-naive patients or lopinavir/ritonavir in ART-experienced patients. Moreover, ART-experienced patients with hyperlipidaemia receiving atazanavir-containing therapy experienced reductions from baseline in total cholesterol, non-high-density lipoprotein cholesterol and trigylceride levels.

The pharmacokinetics of oral atazanavir administered once daily are nonlinear. Greater atazanavir exposure was observed in healthy volunteers than in patients with HIV infection. Boosting with low-dose ritonavir increases atazanavir plasma trough concentrations (the pharmacodynamically linked variable) because of the pharmacokinetic interaction between these drugs. The terminal elimination half-life of unboosted atazanavir was approximately 7 hours in patients with HIV infection or healthy volunteers.

The hepatic cytochrome P450 3A isoenzyme metabolises atazanavir to pharmacologically inactive metabolites that are, along with the unchanged drug, eliminated primarily via the biliary pathway. Pharmacokinetic drug interactions between atazanavir and numerous coadministered drugs, including certain antiretroviral drugs, antimycobacterials, calcium channel antagonists, oral contraceptives and proton pump inhibitors, have been demonstrated.

Therapeutic Efficacy

In phase II or III trials in ART-naive patients receiving a dual-nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen, the efficacy of atazanavir 400mg once daily was similar to that of nelfinavir 750mg three times daily, nelfinavir 1250mg twice daily or efavirenz 600mg once daily after 48 weeks’ treatment. Viral suppression was maintained for an additional 24 weeks in an open-label extension study.

In a randomised 48-week phase III trial in patients also receiving two NRTIs, who had previously failed two HAART regimens, the efficacy of atazanavir 300mg once daily boosted with ritonavir 100mg once daily was noninferior to that of co-formulated lopinavir/ritonavir 400mg/100mg twice daily. However, the efficacy of saquinavir soft gelatin capsules 1200mg once daily plus atazanavir 400mg once daily was inferior to that of lopinavir/ritonavir. The favourable effect of atazanavir plus ritonavir on viral suppression and immunological outcomes was maintained for up to 96 weeks.

Tolerability

Atazanavir in combination with other antiretroviral drugs was generally well tolerated (treatment duration up to 120 weeks). The type of most treatment-related adverse effects was broadly similar between atazanavir recipients and recipients of nelfinavir, efavirenz or co-formulated lopinavir/ritonavir, with the exception of jaundice and scleral icterus, which occurred only in patients receiving atazanavir. Atazanavir-containing regimens were associated with less diarrhoea than nelfinavir- and lopinavir/ritonavir-containing regimens.

The most frequent laboratory abnormality associated with the use of atazanavir-containing regimens was elevated total bilirubin, predominantly of the unconjugated type, which was generally reversible and not associated with elevated aminotransferase levels. Hyperbilirubinaemia infrequently lead to discontinuation. In addition, the incidence of grade 3 or 4 hyperbilirubinaemia in atazanavir recipients was similar between HIV-infected patients positive for hepatitis B and/or C virus and those negative for hepatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV
Table V
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Murphy RL. Reviving protease inhibitors: new data and more options. J Acquir Immune Defic Syndr 2003; 33 Suppl. 1: S43–52

    Article  PubMed  CAS  Google Scholar 

  2. The Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL: http://www.aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf [Accessed 2005 Apr 12]

  3. Raffi F. Releasing the true power of protease inhibitors. Int J STD AIDS 2003 Oct; 14 Suppl. 1: 29–33

    Article  PubMed  Google Scholar 

  4. BHIVA Writing Committee on behalf of the BHIVA Executive Committe. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy: an update [online]. Available from URL: http://www.bhiva.org [Accessed 2005 May 26]

  5. Goldsmith DR, Perry CM. Atazanavir. Drugs 2003; 63(16): 1679–93; discussion 1694-5

    Article  PubMed  CAS  Google Scholar 

  6. Robinson BS, Riccardi KA, Gong Y, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000 Aug; 44(8): 2093–9

    Article  PubMed  CAS  Google Scholar 

  7. Drusano GL, Bilello JA, Preston SL, et al. Hollow-fibre unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis 2001; 183: 1126–9

    Article  PubMed  CAS  Google Scholar 

  8. Bristol-Myers Squibb Company. Reyataz® (atazanavir sulfate) capsules: prescribing information [online]. Available from URL: http://www.bms.com [Accessed 2005 Sep 14]

  9. Gong Y, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000 Sep; 44(9): 2319–26

    Article  PubMed  CAS  Google Scholar 

  10. Colonno R, Rose R, McLaren C, et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189(10): 1802–10

    Article  PubMed  CAS  Google Scholar 

  11. Colonno R, Parkin N, McLaren C, et al. Pathways to atazanavir resistance in treatment-experienced patients and impact of residue 50 substitutions [abstract no. 656]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8–11; San Francisco (CA)

  12. Colonno RJ, Thiry A, Limoli K, et al. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47(4): 1324–33

    Article  PubMed  CAS  Google Scholar 

  13. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples [letter]. AIDS 2003 May 23; 17(8): 1258–61

    Article  PubMed  Google Scholar 

  14. Colonno RJ, Hertogs K, Larder BA, et al. Efficacy of BMS-232632 against a panel of HIV-1 clinical isolates resistant to currently used protease inhibitors [abstract no. 2114]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto (ON), 349

  15. Colonno RJ, Hertogs K, Larder BA, et al. BMS-232632 sensitivity of a panel of HIV-1 clinical isolates resistant to one or more approved protease inhibitors [poster no. 8]. 4th International Workshop on HIV Drug Resistance and Treatment Strategies; 2000 Jun 12–16; Sitges, Spain

  16. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 685–94

    Article  PubMed  CAS  Google Scholar 

  17. Solas C, Colson P, Ravaux I, et al. Predictive factors of atazanavir response including genotypic inhibitory quotient in treatment-experienced patients [abstract no. 1]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec (QC)

  18. Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range [abstract no. 645 plus poster]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)

  19. Gonzalez de Requena D, Bonora S, Cavechia I, et al. Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: definition of therapeutic range [abstract no. 60 plus oral presentation]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec (QC)

  20. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004; 5(4): 201–5

    Article  PubMed  Google Scholar 

  21. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003 Jul 1; 37(1): 113–28

    Article  PubMed  Google Scholar 

  22. Anderson PL, Kiser JJ. Special pharmacology topics in HIV: therapeutic drug monitoring [online]. Available from URL: http://www.medscape.com/viewprogram/415l_pnt [Accessed 2005 Jul 22]

  23. Coakley EP, Chappey C, Maa JF, et al. Determination of phenotypic clinical cutoffs for atazanavir and atazanavir/ritonavir from AI424-043 and AI424-045 [abstract no. 6]. Antiviral Ther 2004; 10 Suppl. 1: S8

    Google Scholar 

  24. Wang S, Mulvey R, Elosua C, et al. Association of HIV-protease inhibitors with insulin resistance is related to potency of inhibition of GLUT4 and GLUT1 activity in adipocytes and myocytes [abstract plus poster]. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2003 Jul 8–11; Paris, L36

  25. Noor MA, Mulvey R, Wang S, et al. Maintenance of favorable in vitro metabolic profile of atazanavir when combined with low dose ritonavir [abstract no. ThOrB1356]. 15th International AIDS Conference; 2004 Jul 11–16; Bangkok

  26. Doran DA, Jones SP, Lagathu C, et al. Mechanisms of insulin resistance in HIV-seronegative individuals acutely treated with ritonavir boosted indinavir and atazanavir regimens [abstract no. 6]. Antiviral Ther 2004 Dec; 9(6): L6

    Google Scholar 

  27. Noor MA, Parker RA, O’Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18: 2137–44

    Article  PubMed  CAS  Google Scholar 

  28. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004 Aug 15; 36(5): 1011–9

    Article  PubMed  CAS  Google Scholar 

  29. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32(1): 18–29

    Article  PubMed  CAS  Google Scholar 

  30. Murphy RL, Sanne I, Cahn P. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17(18): 2603–14

    Article  PubMed  CAS  Google Scholar 

  31. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36(2): 684–92

    Article  PubMed  CAS  Google Scholar 

  32. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005; 21(10): 1683–92

    Article  PubMed  CAS  Google Scholar 

  33. Abbott Laboratories. Norvir (ritonavir capsules): prescribing information [online]. Available from URL: http://www.norvir.com [Accessed 2004 Dec 15]

  34. Johnson M, De Jesus E, Grinsztejn B, et al. Long-term efficacy and durability of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in HIV-infected patients with multiple virologic failures: 96-week results from a randomized, open-label trial, BMS AI424045 [poster no. PL14.4]. Seventh International Congress on Drug Therapy in HIV Infection; 2004 Nov 14–18; Glasgow

  35. Martinez E, Azuaje C, Antela A, et al. Effects of switching to ritonavir-boosted atazanavir on HIV-infected patients receiving antiretroviral therapy with hyperlipidemia [abstract no. 850 plus poster no. K-184] 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA) [online]. Available from URL: http://www.retroconference.org/ [Accessed 2005 Mar 3]

  36. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005 Jun; 39(2): 174–80

    PubMed  Google Scholar 

  37. Sension M, Grinsztejn B, Molina J, et al. AI424067: improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline [abstract no. 858]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA) [online]. Available from URL: http://www.retroconference.org [Accessed 2005 Mar 3]

  38. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy of atazanavir (ATV) based HAART in patients switched from a stable PI or boosted PI (PI/r) treatment. Planned week 24 analysis of a phase IIIb 48-week multicenter, open-label, randomized, prospective study: the SWAN study [poster no. WePe6.3C15]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005 Jul 24–27; Rio de Janeiro

  39. Data on file, Bristol-Myers Squibb Company, 2004 Nov 17

  40. O’Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract no. 504]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30–Feb 2; San Francisco (CA) [online]. Available from URL: http://www.retroconference.org [Accessed 2003 Mar 7]

  41. O’Mara E, Randall D, Stoltz R, et al. BMS-232632: a prospective study of age and gender effects on the single-dose pharmacokinetics in healthy volunteers [abstract plus poster]. 1st International Aids Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8–11; Buenos Aires, 180

  42. O’Mara E, Piliero P, Drusano G, et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of the HIV protease inhibitor BMS-232632 in a protease inhibitor-naive HIV+ population [abstract no. P9]. AIDS 2000; 14 Suppl. 4: S19. Plus poster presented at the Fifth International Congress on Drug Therapy in HIV Infection; 2000 Oct 22–26; Glasgow

    Google Scholar 

  43. O’Mara EM, Smith J, Olsen SJ, et al. BMS-232632: single-oral dose-safety and pharmacokinetic study in healthy volunteers [abstract no. I-242]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego (CA), 440

  44. Solas C, Gagnieu MC, Lanet F, et al. Population pharmacokinetic of atazanavir in HIV-infected patients, [poster no. P4.6]. The 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec (QC)

  45. Agarwala S, Russo R, Mummaneni V, et al. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects [abstract no. H-1716]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA), 274

  46. O’Mara E, Cirincione B, Mummaneni V, et al. Population pharmacodynamic (PD) assessment of the safety and antiretroviral activity of BMS 232632 [abstract plus poster]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16–19; Chicago (IL), 18

  47. Randall D, Agarwala S, Mummaneni V, et al. Tissue compartment concentrations of atazanavir (ATV) in cerebrospinal fluid, seminal fluid and plasma in HIV + subjects [abstract no. H-1711]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA), 273

  48. Bristol-Myers Squibb Company. BMS-232632: atazanavir briefing document May-2003 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1_01_BristolMyersSquibb-Atazanavir.pdf [Accessed 2003 May 15]

  49. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): application number 21-567 [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf [Accessed 2005 Jul 19]

  50. Bristol-Myers Squibb Pharma EEIG. Reyataz® hard capsules: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/reyataz.htm [Accessed 2005 Sep 14]

  51. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18(9): 1291–7

    Article  PubMed  CAS  Google Scholar 

  52. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004 Jun; 48(6): 2091–6

    Article  PubMed  CAS  Google Scholar 

  53. Mummaneni V, Randall D, Chabuel D, et al. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects [abstract no. H-1717]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA), 275

  54. Kaul S, Olszyk C, Ji P, et al. Pharmacokinetics of didanosine enteric coated capsules co-administered with atazanavir or atazanavir/ritonavir [abstract no. 648]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA) [online]. Available from URL: http://www.retroconference.org [Accessed 2005 Mar 3]

  55. Tackett D, Child M, Argarwala S, et al. Atazanavir (ATV): a summary of two pharmacokinetic (PK) drug interaction studies in healthy subjects [poster no. 543]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10–14; Boston (MA) [online]. Available from URL: http://www.retroconference.org [Accessed 2003 Jun 20]

  56. Preston S, Piliero P, O’Mara E, et al. Evaluation of the steady state interaction between atazanavir (ATV) and efavirenz (EFV) [abstract no. 443-W plus poster]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle (WA) [online]. Available from URL: http://www.retroconference.org [Accessed 2003 Jan 30]

  57. Agarwala S, Eley TVC, Child M, et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects [abstract no. 11]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec (QC)

  58. O’Mara E, Randall D, Uderman L, et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects [abstract plus poster no. 1646]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto (ON), 335

  59. Agarwala S, Gray K, Wang Y, et al. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects [abstract no. 658]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA) [online]. Available from URL: http://www.retroconference.org [Accessed 2005 Mar 3]

  60. Agarwala S, Mummaneni V, Randall D, et al. Pharmacokinetic (PK) effect of rifabutin (RIF) on atazanavir (ATV) with and without ritonavir (RTV) in healthy subjects [abstract no. 445-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24–28; Seattle (WA) [online]. Available from URL: http://www.retroconference.org [Accessed 2003 Jan 30]

  61. Burger D, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir and ritonavir in healthy subjects [abstract no. 657]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA) [online]. Available from URL: http://www.retroconference.org [Accessed 2005 Mar 3]

  62. Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects [abstract no. 16]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 Apr 28–30; Quebec (QC)

  63. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract no. A1616 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL), 36

  64. Cahn P, Piliero P, Giordano M, et al. Atazanavir (ATV): antiretroviral efficacy in HIV-infected patients co-infected with hepatitis B and/or C viruses (HBV, HCV) [abstract no. H-1730]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA), 278

  65. Mukherjee J, Wu J, Odeshoo L, et al. Atazanavir (ATV) maintained patient utility and improved quality of life (QOL), comparing favorably to LPV/RTV: 24-week data from BMS043 [abstract no. 7.2/1 plus poster]. 9th European AIDS Conference and 1st EACS Resistance and Pharmacology Workshop; 2003 Oct 25–29; Warsaw, 47

  66. Jemsek JG, Arathoon E, Arlotti M, et al. Atazanavir and efavirenz have similar effects on body fat distribution in antiretroviral-naive patients when combined with fixed-dose zidovudine and lamivudine: 48-week results from the metabolic substudy of BMS AI424-034 [abstract no. LB13 plus oral presentation]. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment: Late Breaker Abstracts; 2003 Jul 13–16; Paris, 288–9

  67. Reyataz gains approval in EU. Scrip 2004 Mar 10; (2933): 24

  68. AVERT. World HIV & AIDS statistics [online]. Available from URL: http://www.avert.org.worldstatinfo.htm [Accessed 2005 Mar 11]

  69. Anderson PL. Pharmacologic perspectives for once-daily antiretroviral therapy. Ann Pharmacother 2004 Nov; 38(11): 1924–34

    Article  PubMed  CAS  Google Scholar 

  70. Moyle GJ. Boosted PIs: competition hots up. AIDS Read 2003 Sep; 13(9): 425–9

    PubMed  Google Scholar 

  71. Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Investig Drugs 2002 Sep; 11(9): 1295–301

    Article  PubMed  CAS  Google Scholar 

  72. Moyle GJ. Lipid abnormalities during ART: It’s the drug, not the class. AIDS Read 2004; 14(1): 15–22

    PubMed  Google Scholar 

  73. Havlir DV, O’Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004 Jun 1; 38: 1599–604

    Article  PubMed  CAS  Google Scholar 

  74. ClinicalTrials.gov. Atazanavir used in combination with other anti-HIV drugs in HIV-infected infants, children, and adolescents [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00006604?order=l [Accessed 2005 Mar 13]

  75. Clavel F, Hance AJ. Medical progress: HIV drug resistance. N Engl J Med 2004 Mar; 350(10): 1023–35

    PubMed  CAS  Google Scholar 

  76. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the international AIDS society-USA panel. JAMA 2004 Jul; 292(2): 251-65

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

At the request of the journal, Bristol-Myers Squibb Company provided a non-binding review of this article.

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Tracy Swainston Harrison & Lesley J. Scott

Authors
  1. Tracy Swainston Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy Swainston Harrison.

Additional information

Various sections of the manuscript reviewed by: P.L. Anderson, Health Sciences Center, University of Colorado, Denver, Colorado, USA; P. Cahn, Fundacion Huesped, Buenos Aires, Argentina; B. Gazzard, St Stephens AIDS Research, Chelsea and Westminster Hospital, London, United Kingdom; J. Kiser, Health Sciences Center, University of Colorado, Denver, Colorado, USA; A. Lazzarin, Divisione di Malattie Infettive, IRCCS, H San Raffaele, Milan, Italy; G. Moyle, St Stephens AIDS Research, Chelsea and Westminster Hospital, London, United Kingdom; R. ter Heine, Department of Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.

Data Selection

Sources: Medical literature published in any language since 1980 on atazanavir, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: MEDLINE search terms were ‘atazanavir’ or ‘CGP-73547’. EMBASE search terms were ‘atazanavir’. AdisBase search terms were ‘atazanavir’ or ‘BMS-232632’. Searches were last updated 5 October 2005.

Selection: Studies in patients with HIV who received atazanavir. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Atazanavir, HIV infection, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, T.S., Scott, L.J. Atazanavir. Drugs 65, 2309–2336 (2005). https://doi.org/10.2165/00003495-200565160-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565160-00010

Keywords

Search

Navigation